Chou Roger, Ballantyne Jane C, Fanciullo Gilbert J, Fine Perry G, Miaskowski Christine
The Oregon Evidence-Based Practice Center, Department of Medicine, Department of Medical Informatics and Clinical Epidemiology, Oregon Health and Science University, Portland, Oregon, USA.
J Pain. 2009 Feb;10(2):147-59. doi: 10.1016/j.jpain.2008.10.007.
Chronic noncancer pain is common and use of opioids is increasing. Previously published guidelines on use of opioids for chronic noncancer pain have been based primarily on expert consensus due to lack of strong evidence. We conducted searches on Ovid MEDLINE and the Cochrane databases through July 2008 to identify studies that addressed one or more of 37 Key Questions that a multidisciplinary expert panel identified as important to be answered to generate evidence-based recommendations on the use of opioids for chronic noncancer pain. A total of 14 systematic reviews, 38 randomized trials not included in a previously published systematic review, and 13 other studies met inclusion criteria. Almost all of the randomized trials of opioids for chronic noncancer pain were short-term efficacy studies. Critical research gaps on use of opioids for chronic noncancer pain include: lack of effectiveness studies on long-term benefits and harms of opioids (including drug abuse, addiction, and diversion); insufficient evidence to draw strong conclusions about optimal approaches to risk stratification, monitoring, or initiation and titration of opioid therapy; and lack of evidence on the utility of informed consent and opioid management plans, the utility of opioid rotation, the benefits and harms specific to methadone or higher doses of opioids, and treatment of patients with chronic noncancer pain at higher risk for drug abuse or misuse.
Currently, clinical decisions regarding the use of opioids for chronic noncancer pain need to be made based on weak evidence. Research funding priorities need to be set to address these critical research needs if the care of patients with chronic noncancer pain is to improve.
慢性非癌性疼痛很常见,阿片类药物的使用正在增加。由于缺乏有力证据,此前发布的关于阿片类药物用于慢性非癌性疼痛的指南主要基于专家共识。我们检索了截至2008年7月的Ovid MEDLINE和Cochrane数据库,以识别那些回答了多学科专家小组确定的37个关键问题中一个或多个问题的研究,这些问题对于生成关于阿片类药物用于慢性非癌性疼痛的循证推荐很重要。共有14项系统评价、38项未纳入此前已发表系统评价的随机试验以及13项其他研究符合纳入标准。几乎所有关于阿片类药物用于慢性非癌性疼痛的随机试验都是短期疗效研究。关于阿片类药物用于慢性非癌性疼痛的关键研究空白包括:缺乏关于阿片类药物长期益处和危害(包括药物滥用、成瘾和转移)的有效性研究;没有足够证据就风险分层、监测或阿片类药物治疗的启动和滴定的最佳方法得出有力结论;缺乏关于知情同意和阿片类药物管理计划的效用、阿片类药物轮换的效用、美沙酮或更高剂量阿片类药物的特定益处和危害以及对药物滥用或误用风险较高的慢性非癌性疼痛患者的治疗的证据。
目前,关于阿片类药物用于慢性非癌性疼痛的临床决策需要基于薄弱的证据做出。如果要改善慢性非癌性疼痛患者的护理,就需要确定研究资金优先事项以满足这些关键研究需求。